Eric Lefkofsky is Fighting Cancer with Technology

By the year 2024, more than 18 million people will have cancer. This is 5million people who will be affected as compared to the year 2014. The good news is; things are going to change due to the introduction of Tempus. The main aim of Tempus is focusing on the way cancer is treated. The technology used is current, and every detail is captured for the advantage of most affected cancer patients.

Tempus does not only focus on data. It also goes a mile ahead to focus on the way information about all types of diseases is collected, analyzed and stored. There is a need to have progress notes which have points of interest of patients from the very beginning up to the end. Tempus uses software that can take in natural language and read characters written by a pen. All these advances and technologies are meant to make all-around structured information.

In most cases, human genome sequencing is very expensive. That is why Tempus is also fighting for cheap coats in conducting this process for patients. If that is achieved, the process of treating cancer will do starting from the cellular level. This will prevent much spread of cancer to other parts of the body.

All the above efforts are affected by Eric Lefkofsky and Tempus to accomplish the best outcomes. It is suspected that Eric Lefkofsky is doing this since his wife once had growth, and he felt bad about it. He is out to fight for people who do not have that power and capital to fight for themselves,thus making the society a better place.

Eric Lefkofsky is one of those people were born in 1969. He is a resident of Southfield, Michigan. He is one those who graduated from the University of Michigan with high-class honors. Eric owns the famous Juris Doctor Degree, and he is known to be very successful. Due to his excellent leadership skills, Eric Lefkofsky is known for holding top positions in many organizations in U.S.A. Some of the organizations are institutes like the Art Institute of Chicago and even children’s home.

For details: www.americaninno.com/chicago/eric-lefkofskys-next-move-curing-cancer-at-tempus/

Eric Lefkofksy believes plummeting cost of gene sequencing may lead to cancer cure

As one indication of the breakneck speed of technological development, it’s instructive to look at the incredible reduction in costs of sequencing human genomes. In 2003, the year that the first complete individual human genome was sequenced, the cost to do so was over $100,000,000. Fast forward 14 years, and the cost of sequencing all of an individual’s genes is a relatively paltry $5,000. This is a quantum leap forward in the accessibility of gene sequencing.

But one man, Eric Lefkofsky, believes that not only will gene sequencing play a star role in future cancer research and treatment but that the cost of sequencing individual genomes will continue to plummet, possibly reaching less than $100 in the next decade. At these price levels, essentially every American’s genome could be easily and cheaply sequenced, leading to an explosion in potentially invaluable data that may lead cancer research to the point of finding a virtual cure.

While Lefkofsky is highly optimistic about the development of cheap gene sequencing and the likely impact that it will have on cancer research and treatment, he still urges caution about the expectations of exactly what such a wealth of new information will likely bring. Lefkofsky says that it is still not hugely likely that a universal cure will be found for all types of cancers. They are simply too heterogeneous, with some cancer types being notoriously resistant to treatment.

Instead, Lefkofsky envisions the coming decades bringing better and better treatments for certain subtypes of cancer. For example, cancers that already have solidly performing, well established treatment regimens, such as breast cancer or prostate cancer, may see additional advances that will all but constitute an actual cure. With others, Lefkofksy believes, treatments may advance to the point where having the disease is similar to those in advanced countries living with AIDS. These cancers will still be a serious disease, but with closely following their treatment regimen, those living with these cancers may be able to effectively survive indefinitely, dying from an unrelated cause.

Lefkofsky says that, while these outcomes would not technically amount to a cure, they are exciting enough to motivate an entire generation of research.

for more info: chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/